HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Research analysts at HC Wainwright boosted their FY2024 earnings per share estimates for CytomX Therapeutics in a research note issued to investors on Monday, November 11th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings per share of $0.14 for the year, up from their previous estimate of ($0.11). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for CytomX Therapeutics' current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for CytomX Therapeutics' Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.12) EPS.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.23. The company had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same quarter last year, the firm posted $0.04 earnings per share.

CytomX Therapeutics Trading Down 2.9 %

CytomX Therapeutics stock traded down $0.03 during mid-day trading on Wednesday, reaching $1.01. The company's stock had a trading volume of 543,830 shares, compared to its average volume of 2,546,970. CytomX Therapeutics has a twelve month low of $0.98 and a twelve month high of $5.85. The business has a 50 day moving average price of $1.13 and a 200-day moving average price of $1.46. The firm has a market cap of $79.04 million, a price-to-earnings ratio of 6.03 and a beta of 1.06.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CTMX. Congress Park Capital LLC grew its holdings in shares of CytomX Therapeutics by 393.3% in the 2nd quarter. Congress Park Capital LLC now owns 1,153,220 shares of the biotechnology company's stock worth $1,407,000 after acquiring an additional 919,420 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of CytomX Therapeutics by 206.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,238,499 shares of the biotechnology company's stock valued at $1,511,000 after acquiring an additional 833,825 shares during the last quarter. Sei Investments Co. bought a new stake in shares of CytomX Therapeutics in the second quarter valued at approximately $467,000. Candriam S.C.A. acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth approximately $256,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in CytomX Therapeutics in the first quarter worth about $124,000. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.